{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:42:09Z","timestamp":1788428529468,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["84317"],"award-info":[{"award-number":["84317"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["702603"],"award-info":[{"award-number":["702603"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00520-018-4583-5","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T09:55:14Z","timestamp":1544262914000},"page":"2789-2797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pain in patients with newly diagnosed or relapsed acute leukemia"],"prefix":"10.1007","volume":"27","author":[{"given":"Adir","family":"Shaulov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Rodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie B.","family":"Caraiscos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa W.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rydall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-0244","authenticated-orcid":false,"given":"Camilla","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,8]]},"reference":[{"key":"4583_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152. \n                    https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"4583_CR2","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","volume":"114","author":"MS Tallman","year":"2009","unstructured":"Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114:5126\u20135135. \n                    https:\/\/doi.org\/10.1182\/blood-2009-07-216457","journal-title":"Blood"},{"key":"4583_CR3","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"4583_CR4","first-page":"302","volume":"8","author":"F Bauduer","year":"2000","unstructured":"Bauduer F, Capdupuy C, Renoux M (2000) Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 8:302\u2013306","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"4583_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0145-2126(02)00262-X","volume":"27","author":"AM Stalfelt","year":"2003","unstructured":"Stalfelt AM, Brodin H, Pettersson S, Ekl\u00f6f A (2003) The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res 27:481\u2013488","journal-title":"Leuk Res"},{"key":"4583_CR6","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2352-3026(15)00111-8","volume":"2","author":"TW LeBlanc","year":"2015","unstructured":"LeBlanc TW, Smith JM, Currow DC (2015) Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series. Lancet Haematol 2:e334\u2013e338. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(15)00111-8","journal-title":"Lancet Haematol"},{"key":"4583_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/jpm.2007.0184","volume":"11","author":"NA Fadul","year":"2008","unstructured":"Fadul NA, El Osta B, Dalal S et al (2008) Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med 11:422\u2013427. \n                    https:\/\/doi.org\/10.1089\/jpm.2007.0184","journal-title":"J Palliat Med"},{"key":"4583_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/ehm.10.79","volume":"4","author":"P Niscola","year":"2011","unstructured":"Niscola P, Tendas A, Scaramucci L, Giovaninni M, Cupelli L, de Sanctis V, Brunetti GA, Bondanini F, Palumbo R, Lamanda M, Battistini R, Cartoni C, Romani C, Arcuri E (2011) Pain in malignant hematology. Expert Rev Hematol 4:81\u201393. \n                    https:\/\/doi.org\/10.1586\/ehm.10.79","journal-title":"Expert Rev Hematol"},{"key":"4583_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.leukres.2013.02.009","volume":"37","author":"C Zimmermann","year":"2013","unstructured":"Zimmermann C, Yuen D, Mischitelle A, Minden MD, Brandwein JM, Schimmer A, Gagliese L, Lo C, Rydall A, Rodin G (2013) Symptom burden and supportive care in patients with acute leukemia. Leuk Res 37:731\u2013736. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2013.02.009","journal-title":"Leuk Res"},{"key":"4583_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/pon.2092","volume":"22","author":"G Rodin","year":"2013","unstructured":"Rodin G, Yuen D, Mischitelle A, Minden MD, Brandwein J, Schimmer A, Marmar C, Gagliese L, Lo C, Rydall A, Zimmermann C (2013) Traumatic stress in acute leukemia. Psychooncology 22:299\u2013307. \n                    https:\/\/doi.org\/10.1002\/pon.2092","journal-title":"Psychooncology"},{"key":"4583_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/pon.4488","volume":"27","author":"G Rodin","year":"2018","unstructured":"Rodin G, Deckert A, Tong E, Le LW, Rydall A, Schimmer A, Marmar CR, Lo C, Zimmermann C (2018) Traumatic stress in patients with acute leukemia: a prospective cohort study. Psychooncology 27:515\u2013523. \n                    https:\/\/doi.org\/10.1002\/pon.4488","journal-title":"Psychooncology"},{"key":"4583_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1176\/ajp.140.6.734","volume":"140","author":"R Katzman","year":"1983","unstructured":"Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 140:734\u2013739. \n                    https:\/\/doi.org\/10.1176\/ajp.140.6.734","journal-title":"Am J Psychiatry"},{"key":"4583_CR13","unstructured":"Karnofsky DA, Burchenal H\u00a0(1949) The clinical evaluation of chemotherapeutic agents. In: McCloud CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191\u2013205"},{"key":"4583_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1182\/asheducation-2009.1.396","volume":"2009","author":"JM Rowe","year":"2009","unstructured":"Rowe JM (2009) Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program 2009:396\u2013405. \n                    https:\/\/doi.org\/10.1182\/asheducation-2009.1.396","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4583_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ajh.21034","volume":"83","author":"JM Brandwein","year":"2008","unstructured":"Brandwein JM, Gupta V, Schuh AC, Schimmer AD, Yee K, Xu W, Messner HA, Lipton JH, Minden MD (2008) Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol 83:54\u201358. \n                    https:\/\/doi.org\/10.1002\/ajh.21034","journal-title":"Am J Hematol"},{"key":"4583_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","volume":"9","author":"S Amadori","year":"1991","unstructured":"Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 9:1210\u20131214. \n                    https:\/\/doi.org\/10.1200\/JCO.1991.9.7.1210","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4583_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s002770050239","volume":"73","author":"IM Huhmann","year":"1996","unstructured":"Huhmann IM, Watzke HH, Geissler K, Gisslinger H, J\u00e4ger U, Kn\u00f6bl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas OA, Lechner K (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265\u2013271","journal-title":"Ann Hematol"},{"key":"4583_CR18","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, Portenoy RK, Thaler HT, Kornblith AB,\u00a0Lepore JM, Friedlander-Klar H, Kiyasu E,\u00a0Sobel K, Coyle N, Kemeny N, Norton L, Scher H (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer Oxf Engl 1990(30A):1326\u20131336","DOI":"10.1016\/0959-8049(94)90182-1"},{"key":"4583_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","volume":"146","author":"JM Storring","year":"2009","unstructured":"Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KWL, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM (2009) Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 146:76\u201385. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07712.x","journal-title":"Br J Haematol"},{"key":"4583_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00520-013-2049-3","volume":"22","author":"TL Deshields","year":"2014","unstructured":"Deshields TL, Potter P, Olsen S, Liu J (2014) The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 22:1089\u20131096. \n                    https:\/\/doi.org\/10.1007\/s00520-013-2049-3","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"4583_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00277-005-0062-4","volume":"85","author":"P Niscola","year":"2006","unstructured":"Niscola P (2006) Opioids in pain management of blood-related malignancies. Ann Hematol 85:489\u2013501","journal-title":"Ann Hematol"},{"key":"4583_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0885-3924(03)00074-5","volume":"25","author":"JE Tranmer","year":"2003","unstructured":"Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420\u2013429","journal-title":"J Pain Symptom Manage"},{"key":"4583_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2407-13-6","volume":"13","author":"JK Cataldo","year":"2013","unstructured":"Cataldo JK, Paul S, Cooper B, Skerman H, Alexander K, Aouizerat B, Blackman V, Merriman J, Dunn L, Ritchie C, Yates P, Miaskowski C (2013) Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer 13:6. \n                    https:\/\/doi.org\/10.1186\/1471-2407-13-6","journal-title":"BMC Cancer"},{"key":"4583_CR24","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/j.pain.0000000000000456","volume":"157","author":"V Posternak","year":"2016","unstructured":"Posternak V, Dunn LB, Dhruva A, Paul SM, Luce J, Mastick J, Levine JD, Aouizerat BE, Hammer M, Wright F, Miaskowski C (2016) Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain. Pain 157:892\u2013900. \n                    https:\/\/doi.org\/10.1097\/j.pain.0000000000000456","journal-title":"Pain"},{"key":"4583_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-010-0865-2","volume":"19","author":"WY Cheung","year":"2011","unstructured":"Cheung WY, Le LW, Gagliese L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 19:417\u2013423. \n                    https:\/\/doi.org\/10.1007\/s00520-010-0865-2","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"4583_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/pon.2114","volume":"22","author":"MRM Visser","year":"2013","unstructured":"Visser MRM, Oort FJ, van Lanschot JJB, van der Velden J, Kloek JJ, Gouma DJ, Schwartz CE, Sprangers MAG (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangers and Schwartz model. Psychooncology 22:515\u2013522. \n                    https:\/\/doi.org\/10.1002\/pon.2114","journal-title":"Psychooncology"},{"key":"4583_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1200\/JCO.1984.2.8.865","volume":"2","author":"SB Kahn","year":"1984","unstructured":"Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH (1984) Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol Off J Am Soc Clin Oncol 2:865\u2013870. \n                    https:\/\/doi.org\/10.1200\/JCO.1984.2.8.865","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4583_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, D\u00f6hner H, Gratwohl A, Pabst T, Verhoef G, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON), German AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235\u20131248. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0901409","journal-title":"N Engl J Med"},{"key":"4583_CR29","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin M, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE, UK NCRI AML Study Group (2015) A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125:3878\u20133885. \n                    https:\/\/doi.org\/10.1182\/blood-2015-01-623447","journal-title":"Blood"},{"key":"4583_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.clml.2017.06.018","volume":"17","author":"R Portugal","year":"2017","unstructured":"Portugal R, Lyrio R, Loureiro M, Urago K, Bard J, Borchardt A, Garnica M, Nucci M (2017) Daunorubicin 90 mg\/m2 in acute myeloid leukemia induction: increased toxicity in young patients. Clin Lymphoma Myeloma Leuk 17:527\u2013531. \n                    https:\/\/doi.org\/10.1016\/j.clml.2017.06.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"97","key":"4583_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.14219\/jada.archive.1978.0304","volume":"1939","author":"ST Sonis","year":"1978","unstructured":"Sonis ST, Sonis AL, Lieberman A (1978) Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1939(97):468\u2013472","journal-title":"J Am Dent Assoc"},{"key":"4583_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/cncr.28614","volume":"120","author":"D Hui","year":"2014","unstructured":"Hui D, Didwaniya N, Vidal M, Shin SH, Chisholm G, Roquemore J, Bruera E (2014) Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer 120:1572\u20131578. \n                    https:\/\/doi.org\/10.1002\/cncr.28614","journal-title":"Cancer"},{"key":"4583_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/0269216310391692","volume":"25","author":"DA Howell","year":"2011","unstructured":"Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR (2011) Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med 25:630\u2013641. \n                    https:\/\/doi.org\/10.1177\/0269216310391692","journal-title":"Palliat Med"},{"key":"4583_CR34","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1200\/JOP.2014.001537","volume":"10","author":"OO Odejide","year":"2014","unstructured":"Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA (2014) End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract 10:e396\u2013e403. \n                    https:\/\/doi.org\/10.1200\/JOP.2014.001537","journal-title":"J Oncol Pract"},{"key":"4583_CR35","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/annonc\/mdv028","volume":"26","author":"D Hui","year":"2015","unstructured":"Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E (2015) Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol Off J Eur Soc Med Oncol 26:1440\u20131446. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv028","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4583_CR36","doi-asserted-by":"publisher","unstructured":"LeBlanc TW, O\u2019Donnell JD, Crowley-Matoka M,\u00a0Rabow MW, Smith CB,\u00a0White DB, Tiver GA, Arnold RM, Schenker Y (2015) Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract 11:e230\u2013e238. \n                    https:\/\/doi.org\/10.1200\/JOP.2014.001859","DOI":"10.1200\/JOP.2014.001859"},{"key":"4583_CR37","doi-asserted-by":"publisher","unstructured":"El-Jawahri A, LeBlanc T, VanDusen H,\u00a0Traeger L, Greer JA, Pirl\u00a0WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen\u00a0YA, Lee SS, Temel JS (2016) Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 316:2094\u20132103. \n                    https:\/\/doi.org\/10.1001\/jama.2016.16786","DOI":"10.1001\/jama.2016.16786"},{"key":"4583_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.leukres.2016.07.012","volume":"48","author":"C Zimmermann","year":"2016","unstructured":"Zimmermann C (2016) Palliative care for patients with hematological malignancies: time for a new model. Leuk Res 48:78\u201379. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2016.07.012","journal-title":"Leuk Res"},{"key":"4583_CR39","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1200\/JOP.2014.000968","volume":"10","author":"TW LeBlanc","year":"2014","unstructured":"LeBlanc TW (2014) Palliative care and hematologic malignancies: old dog, new tricks? J Oncol Pract 10:e404\u2013e407. \n                    https:\/\/doi.org\/10.1200\/JOP.2014.000968","journal-title":"J Oncol Pract"},{"key":"4583_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/leu.2013.176","volume":"28","author":"M Othus","year":"2014","unstructured":"Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E (2014) Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u201cintense\u201d induction regimens: a report from SWOG and MD Anderson. Leukemia 28:289\u2013292. \n                    https:\/\/doi.org\/10.1038\/leu.2013.176","journal-title":"Leukemia"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4583-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T19:21:58Z","timestamp":1575746518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4583-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4583-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,8]]},"assertion":[{"value":"16 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the University Health Network (UHN) Research Ethics Board (REB #06-0387-CE). All study participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.D. Schimmer reports personal fees and grants outside this submitted work from Novartis, Takeda Pharmaceuticals, Aeglea Pharmaceuticals, and Trillium Therapeutics. The remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Findings were presented in part at the Multinational Association of Supportive Care in Cancer (MASCC)\/ISOO 2017 Annual Meeting on Supportive Care in Cancer, Washington, DC, USA, June 22\u201324, 2017 (e-poster presentation); early\/preliminary findings were presented at the 20th International Congress on Palliative Care, Montreal, Quebec, Canada, September 9\u201312, 2014 (poster presentation); the MASCC\/ISOO 2014 Annual Meeting on Supportive Care in Cancer, Miami, Florida, United States, June 26\u201328, 2014 (oral presentation); the Hospice Palliative Care Ontario Annual Conference, Toronto, Ontario, Canada, April 27\u201329, 2014 (oral presentation); and the 9th Annual Advanced Learning in Palliative Medicine Conference, Vancouver, British Columbia, Canada, June 13\u201315, 2013 (oral presentation).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}}]}}